Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and ignited a global pandemic with detrimental impacts on health systems across the world. This novel virus caught the globe unprepared without targeted medical countermeasures (MCMs), such as therapeutics, to treat individuals with coronavirus disease (COVID-19). As the pandemic progressed and scientific progress was rapidly stimulated, the therapeutic toolkit to treat COVID-19 evolved to include monoclonal antibodies. Monoclonal antibody therapeutics to treat COVID-19 are composed of laboratory-synthesized SARS-CoV-2 neutralizing antibodies, most often isolates from infected individuals, and isolated for specific immunologic properties such as binding, neutralization, and effector functions. Multiple formulations and forms of administration of monoclonal antibodies have been authorized by US Food and Drug Administration’s under Emergency Use Authorization (EUA) for both post-exposure prophylaxis and treatment. Recent clinical trials on monoclonal antibody therapies suggest that early use of these drugs can reduce COVID-19 symptom severity, SARS-CoV-2 viral load, and hospitalization in infused outpatient populations as compared to individuals given placebos. Real-world effectiveness studies have also provided evidence that monoclonal antibody infusions reduce hospitalization rates in high-risk patient populations. These monoclonal antibody therapies are currently administered as intravenous infusions to treat individuals with mild to moderate COVID-19. The EUAs also specify monoclonal antibody infusion eligibility requirements for potential patients at high risk for COVID-19 complications, such as age, body mass index, and pre-existing conditions (SI Table 1). EUAs are regulatory tools used...
during public health emergencies, such as pandemics, to expand use, system implementation, and further study of new therapeutics.\textsuperscript{10} Despite the EUAs and promising clinical trial results, monoclonal antibody therapies are currently underutilized as a treatment for COVID-19 across the United States. This is hypothesized to be due to gaps in outreach to both providers and patient communities, strict EUA criteria, and infusion site implementation barriers during the ongoing pandemic, such as staffing, resources, and infection control.\textsuperscript{11} Incorporating monoclonal antibodies into COVID-19 response efforts may relieve stress on medical centers through reducing disease severity and hospitalizations.\textsuperscript{12} Monoclonal antibody use is increasing in some settings across the United States, but there is limited research on the implementation of this therapy, resources needed to maintain an infusion site, and lessons learned to inform the scale-up of this pandemic response tool. Monoclonal antibody therapeutics may also play a critical role in future emerging biological threats, including the newly described, emerging variant SARS-CoV-2 isolates, as they can be rapidly manufactured and can be used as a treatment before other MCMs, such as vaccines, evaluated, and distributed.\textsuperscript{13} Vaccines may also require multiple weeks or doses to elicit protection, while monoclonal antibodies serve as a treatment to reduce the burden of a novel pathogen. It is critical to learn from the ongoing implementation of monoclonal antibody infusions during the COVID-19 pandemic to inform the scale-up of this therapy, and other biologics, during the current and future emergencies.

The purpose of this investigation was to describe monoclonal antibody infusion site implementation and requirements during the COVID-19 pandemic using data from 3 sites in the United States, supported by the Office of the Assistant Secretary for Preparedness and Response (ASPR). A set of standard metrics was utilized to evaluate site infusion process staffing model, resources, strengths, and challenges. Diagrams of the monoclonal antibody infusion process components and infusion site physical environment illustrate various therapy implementation layouts. The descriptive metrics analysis informs the implementation of a monoclonal antibody infusion site for the COVID-19 pandemic response efforts and for future use to tackle emerging infectious disease threats. This is a critical window during the pandemic in the United States to examine the implementation of monoclonal antibody infusion sites for outpatients as the response is currently marked by recent therapy EUAs and the steadily growing mass distribution of COVID-19 vaccines.

**Infusion Site Process Assessment**

Data were collected from 3 medical centers in the United States, El Centro Regional Medical Center (El Centro, CA), TMC HealthCare (Tucson, AZ), and Sunrise Hospital and Medical Center (Las Vegas, NV) between January and February 2021. These sites recently implemented monoclonal antibody infusions during the pandemic to treat individuals with mild and moderate COVID-19 using EUA criteria and by collaborating with ASPR’s National Disaster Medical System (NDMS) Disaster Medical Assistance Teams (DMATs). All 3 medical sites then transitioned to maintaining their own monoclonal antibody infusion sites without ASPR support and incorporated monoclonal antibody infusion into their COVID-19 pandemic response workflows. This investigation was concerned with describing the infusion site process workflows after the DMATs departed and the medical systems transitioned their processes to ensure sustainability during the COVID-19 pandemic. These sites were selected due to their early adoption of monoclonal antibody delivery while under pandemic stress as COVID-19 “hotspots.” The 3 sites also delivered care to diverse and underserved patient populations, and exhibited different process approaches, infrastructures, and physical locations that can inform monoclonal antibody infusion process scale-up across the United States. Two of the sites were temporary tent-based infusion sites and 1 site was a converted former primary care clinic. This clinical support activity was conducted as part of the ASPR public health response to the COVID-19 pandemic and at the request of the host institutions. Under the US Department of Health and Human Services, Office of Health Research Protection guidelines, it was judged a non-research COVID-19 response activity. The Johns Hopkins University Applied Physics Laboratory (JHU/APL) Environmental Health Services Board and all 3 medical sites also deemed this work non-human subjects research exempt from institution review board approval.

**Data Collection and Analysis**

Data were collected through 3 mechanisms to inform the monoclonal antibody infusion process assessment, model, and recommendations: (1) key informant interviews, (2) on-site observations, and (3) infusion records. A process assessment framework informed the 7 key metrics on which data were collected to ensure standard data collection at each site (SI Figure 1): logistics, timing, staffing, physical environment, resources, monitoring and resilience, and engagement (SI Table 2). The 7 framework metrics describe critical quantitative and qualitative characteristics of the infusion process to inform the assessment and propose future recommendations.

Semi-structured key informant interviews were conducted at each site using an interview guide to collect data on infusion process assessment metrics to ensure standard data collection. Interviews were conducted with the medical center’s Chief Medical Officer, infusion site logistics lead, infection control lead, director of pharmacy, and infusion site staff. Each of the 3 different medical centers’ monoclonal antibody infusion sites was visited by the study team to observe and map the infusion process workflow. Each step in the infusion process was timed for multiple patients, and the staff, resources, and information needed for the step were recorded. The on-site observations also facilitated validating data from the key informant interviews.

A descriptive analysis of the monoclonal antibody infusion process was conducted to examine the timing, staffing needs, resources, and information flow of each component of the process. The process was examined from patient engagement through the infusion appointment and discharge from the infusion site. The physical environment of each infusion site was also mapped to analyze resource and implementation needs for this new therapy option. Data on each process metric from the process assessment framework were synthesized and compiled for each site.

**Infusion Site Workflow and Metrics**

A descriptive analysis of 3 medical center monoclonal antibody infusion sites was conducted using a process assessment to inform recommendations to strengthen infusion site implementation during current pandemic response efforts. This investigation evaluated the process of monoclonal antibody infusion and staffing equipment, physical space, and resource requirements during the COVID-19 pandemic. A general monoclonal antibody infusion...
site workflow process (Figure 1) was developed to integrate the data from the 3 data collection sites. It is important to note that there was not a single standard monoclonal antibody infusion site process workflow. Each site exhibited common process components, staffing models, and resources, yet adapted the system to address local policies, patient populations, and medical center characteristics. An effective monoclonal antibody infusion site optimized the volume of infused patients and minimized patient appointment time and stress on the underlying medical system.

The sites exhibited 2 major medical center mechanisms of implementing a monoclonal antibody infusion site: (1) an outpatient infusion clinic model, and (2) an emergency department (ED) medication visit model (Table 1). Site 1 employed a model tied to ED operations, while Sites 2 and 3 operated as outpatient infusion sites co-located with a medical center. The infusion sites also presented 2 appointment types: 24/7 walk-up and scheduled appointments during business hours. The 3 sites started infusions at different times: first Site 1 started on December 30, 2020, and Sites 2 and 3 initiated infusions the same week, respectively, on January 7 and 8, 2021. Site 1 completed 397 infusions since starting the site with an average rate of 16 infusions per day. Last, Site 3 completed 402 infusions with 824 patients infused, amounting to a rate of approximately 16 infusions per day.

Generally, the process components were initiated by a prospective patient testing positive for SARS-CoV-2, and with scheduling-based infusion sites, patients having first to obtain a provider referral for monoclonal antibody treatment with confirmation that they meet the EUA robust criteria, and timely local SARS-CoV-2 test result turnaround was critical to effective monoclonal antibody implementation, as the current EUA requires the infusion to occur within 10 days of symptom onset in patients with a documented positive COVID-19 viral test result. Areas with SARS-CoV-2 testing turnaround close to 1 week delayed patient referral and created monoclonal antibody uptake obstacles. Infusion site appointments had 3 major components. The first component was a pre-infusion intake process to confirm patient eligibility, collect vitals, obtain patient consent, and insert an IV. The next component was the monoclonal antibody infusion process, which ranged from 16–60 minutes depending upon the specific therapy available and size of infusion bags. This time was EUA-dependent and this process must remain flexible to changes in infusion requirements, as the guidelines changed from 60 to 16 minutes during the study period. The last component was the EUA-specified 60-minute patient observation period of each patient to monitor for any adverse events.

Three process components contributed the most to patient visit time variability: (1) scheduling appointments, (2) pre-infusion patient intake, and (3) monoclonal antibody coordination with the medical center pharmacy. These 3 process components also created stresses on already constrained staffing resources. A critical barrier of the infusion process at each of the 3 sites was the pharmacy’s preparation of the monoclonal antibody and coordination with the infusion site on therapy doses and timing. Scheduling-based infusion site pharmacies were equipped with data to enable pre-preparation of monoclonal antibody doses in batches before patients arrive. The 3 infusion sites emphasized that coordination with the pharmacy is difficult due to physical proximity and the need to conserve any prepared doses. Monoclonal antibody infusion process workflows were strongly shaped by EUA requirements regarding drug preparation, storage, timing, and delivery.

Infusion Site Staffing

Similar to the infusion process components, the infusion site staffing metrics varied between sites. The different staffing models relied on the same underlying requirements to ensure monoclonal antibody referral, prescription, preparation, and administration (Table 2). Staffing models differed due to state policies and the different underlying staffing structures of the 3 medical centers. Each staffing model consisted of an advanced practice provider (APP) or physician, a nursing team, and a pharmacy team. The infusion site operations relied heavily on the nursing team, and the more effective infusion process workflows separated the nursing team into

Figure 1. General monoclonal antibody infusion site process workflow examining the network of physical environments, patients, information, calls, staff, and resources, informed by the workflows and assessments of each data collection site.
Physical Environment and Resources

The different external and internal physical environments exhibited by the 3 monoclonal antibody infusion sites were influenced by infection control, resource transport, staffing, and emergency response plan considerations (SI Figures 2–3). Monoclonal antibody recipients are all laboratory-confirmed SARS-CoV-2-positive patients and likely infectious; consequently, it was critical to separate the infusion site from other medical center operations with uninfected individuals. Two of the sites created temporary tent-based infusion sites next to their ED to maintain a separate physical space and HVAC system for infection control purposes but remain near emergency services for potential adverse events and the pharmacy for monoclonal antibody preparations. One site converted a former primary care clinic located a short distance away from the main medical center into a monoclonal antibody infusion site. This building was only being used by monoclonal antibody patients and the therapy was transferred by a driving courier from the pharmacy in the main medical center campus to the site.

The sites differed in the total number of patients who could be infused at one point in time. While the indoor site allocated 6 rooms for infusion, the 2 tent sites had 10 and 30 infusion chairs (Figure 2). Medical and technological infusion site resources were needed to perform the infusion process, record patient data, and ensure an infection-controlled environment. The resources did not vary greatly between the 3 infusion sites; however, some sites improved the overall monoclonal antibody infusion process by using a mobile, miniature refrigeration unit to store batches of the monoclonal antibody, and scanners to rapidly send prescriptions and paperwork (Table 3). The temporary tent sites required more infrastructure resources such as electricity sources, power strips, lights, HVAC systems, and generators to remain self-sufficient while adjacent to the medical center. At the current stage in the pandemic, the 3 infusion sites did not report any supply chain barriers related to the physical environment and infusion-related resources.
Table 2. Monoclonal antibody infusion process staffing metrics from the 3 National Disaster Medical System-supported infusion sites and strengths and challenges related to staffing and implementation decision-making

| Staffing metrics | Infusion site 1 | Infusion site 2 | Infusion site 3 | Implementation considerations |
|------------------|----------------|----------------|----------------|------------------------------|
| **Strengths**    |                |                |                |                              |
| Full-time staff  | 0              | 5-6            | 5-6            |                              |
| Support staff    | 3-6            | 4              | 2-3            |                              |
| Total staff      | 3-6            | 9-10           | 7-9 (1 volunteer) |                              |

**Resilience, Monitoring, and Engagement**

Sustaining infusion sites through the pandemic required process resilience, monitoring, and engagement (Table 4). Two major barriers that affected process resilience were monoclonal antibody infusion-related adverse events and disruptions to the infusion schedule. The 3 sites had comprehensive plans and resources in place to address a potential adverse event, including the presence of a crash cart at the infusion site, availability of oxygen, patient transport equipment, and medications to treat allergic reactions. The temporary tent sites were also placed adjacent to the ED of the medical centers to ensure close proximity to emergency services if needed. This was a challenge for the off-site physical environment of Site 2 as emergency services would need to be called in the event of an adverse reaction requiring further medical assistance. Disturbances to the schedule were not a potential challenge for Site 1 as it was walk-in based including referrals of ED patients. Sites 2 and 3 emphasized the importance of quickly refrigerating or relabeling an unused monoclonal antibody dose due to patients not arriving for their appointments. This proved to be difficult for sites on Fridays as they were closed on the weekends, and the preservative-free monoclonal antibody drug products must be infused within 24 hours of preparation. Infusion process monitoring and evaluation varied greatly from site to site: 1 site did not conduct any real-time analysis and other sites implemented dashboards to monitor progress such as average patients per day, tracking adverse events, and patient appointment time estimates. A large barrier to monoclonal antibody infusion site implementation during the COVID-19 pandemic was engagement with patients and providers for education, outreach, and referrals.

**Discussion**

In these 3 ASPR-supported monoclonal antibody infusion sites, our primary finding was that existing processes do not need to be reinvented to implement a successful infusion site during public health emergencies, as the therapy lends itself well to integration into existing outpatient infusion processes and ED/Urgent Care medical visits. The sites implemented various personnel, equipment, and resource modifications to successfully provide monoclonal antibody therapies in communities with large burdens of COVID-19. The general structures of the 3 monoclonal antibody process workflows described here are similar and have consistent
major compartmental steps. Process variations were introduced to address state and local requirements on staffing, prescription orders, and to maintain medical center integration with other COVID-19 response workflows. As the COVID-19 pandemic and EUAs evolve, infusion site implementation and maintenance must remain adaptable to changes in therapeutic administration, clinical criteria, requirements, resources, and site needs.

Although a successful monoclonal antibody infusion site can be implemented with minimal staffing needs from the underlying health care system, the physical environment, resources, and work require planning and systems integration to ensure effectiveness, robust infection control, and safety. Medical volunteers or local paramedics can aid in staffing needs and also reduce the burden on the health care system during an emergency. The major strengths of these diverse sites derived from strong community and medical provider engagement on monoclonal antibodies, resilience to process disruptions, and optimized workflows of separating pre-infusion tasking and infusion-related activities between 2 nursing teams. The 3 sites demonstrated successful implementation during a pandemic through strong leadership and staff, collaboration with the NDMS, and flexibility to test and evaluate infusion process workflows. Common barriers and challenges across the sites included coordinating the preparation of the monoclonal antibody in the pharmacy, as it was not prepared at bedside. However, it is important to note that the EUA allows for the therapy to be prepared at bedside and this preparation mechanism may be more effective at particular types of sites, such as nursing homes, and at-home infusions. Infusion sites that scheduled patients were better able to address this barrier by batch preparing infusion bags and storing them in a refrigerator. Scheduling monoclonal antibody infusion appointments was time- and staff-intensive; however, scheduling enabled more efficient workflows and monoclonal antibody preparation.

Confirming patient test positivity and scheduling individuals within 10 days of their symptom onset were other barriers to optimal monoclonal antibody infusions. Rigorous and timely testing and result communication was a necessary foundation for infusion site success due to the requirement for evidence of a positive test result. Future EUA changes and additional authorizations may address some of the logistical challenges and barriers in infusion site implementation such as reducing infusion times, changing storage and preparation requirements, and expanding patient criteria. Demand for this therapy has not yet been maximized in many communities, and the sites’ process workflows can
Table 3. Monoclonal antibody infusion process physical environment and resource metrics from the 3 National Disaster Medical System-supported infusion sites and related strengths and challenges

| Physical environment & resource metrics | Site 1 | Site 2 | Site 3 | Implementation considerations |
|----------------------------------------|--------|--------|--------|-------------------------------|
| **Physical environment type**          | Temporary tents with heating, venting, and air condition (HVAC), electricity, generator, and outdoor mobile restroom | Offsite indoor infusion site | Temporary tent with HVAC, electricity, generator, and outdoor mobile restroom and handwashing station | Temporary tents can lend themselves to easier infection control measures. Temporary tents may allow for closer proximity to emergency services. Indoor infusion sites can be more climate resilient and may have pre-existing resources such as electricity and furniture. |
| **Monoclonal antibody type(s) infused**| Bamlanivimab and REGN-COV2 | Bamlanivimab | Bamlanivimab | Easier to allocate and share common resources, such as infusion towers, when in a tent layout. Bamlanivimab recently EUA approved reduced infusion times to as little as 16 minutes. Refrigeration capacity at infusion site can allow for unused preparations to be stored for 24-36 hours for future use, depending on specific therapy. Phone capabilities allow for communication with the medical left, emergency services, and other stakeholders. Integrating the infusion site technology with the electronic health record system and electronic communications supported more effective processes. |
| **Medical resources**                  | Intravenous (IV) supplies | IV supplies | IV supplies | Tent sites require technological and furniture resources and may require resource storage during off hours. REGN-COV2 can take approximately 10-15 minutes longer to prepare due to vials and packaging. Products are both preservative-free and require immediate use after preparation unless refrigerated. Medical lefts needed to ensure open supply chains for required medical resources. Infusion sites must be incorporated into biohazard waste medical left plans. |

(Continued)
Table 3. (Continued)

| Physical environment & resource metrics | Site 1 | Site 2 | Site 3 | Implementation considerations |
|----------------------------------------|--------|--------|--------|-------------------------------|
| Technologic resources                  |        |        |        |                               |
| Vitals monitors                        | Vitals monitors | Vitals monitors | Computer to interface with electronic health record |
| Computer to interface with electronic health record | Computer to interface with electronic health record | Computer to interface with electronic health record |
| Fax machine                            | Infusion site specific phone line | Fax machine to interface with pharmacy |
| Lights                                 | Infusion site specific phone line | Infusion site specific phone line |
| Power cords                            | Lights | Lights | Lights | Lights |
| Electricity generator                  | Electricity generator | Electricity generator | Electricity generator |
| HVAC system                            | HVAC system | HVAC system | HVAC system |

Table 4. Monoclonal antibody infusion process resilience, monitoring, and engagement metrics from the 3 National Disaster Medical System-supported infusion sites and related strengths and challenges

| Resilience, monitoring, & engagement | Site 1 | Site 2 | Site 3 | Implementation considerations |
|-------------------------------------|--------|--------|--------|-------------------------------|
| Potential adverse events protocol   | Crash-cart located within the tent | Crash-cart located within the tent | Crash-cart located within the tent | Strong engagements with the local community members, providers, and other medical sites built trust and increased therapeutic demand |
|                                    | Site located adjacent to Emergency Department (ED) to address potential adverse events | Offsite of main medical campus, must call 911 for adverse events or related-emergencies | Site located adjacent to ED to address potential adverse events |
| Schedule disruption impacts         | Lacked pre-established schedule | Doses from scheduled patients who do not arrive were stored in refrigerator for next infusion appointment block within 24 hours | Doses from scheduled patients who do not arrive are stored in refrigerator for next infusion appointment block within 24 hours | Difficult to engage and build trust with particular patient and vulnerable communities due to misinformation and disinformation on the COVID-19 pandemic |
| Monitoring & evaluation of infusion site | No formal monitoring and evaluation tools | Utilized dashboard and electronic health records to monitor and evaluate progress and adjust process | Uses whiteboard and electronic health records to monitor, evaluate, and adjust infusion process and schedule |
| Patient engagement                  | Social media engagement such as Facebook Live | Newspaper and online media | Newspaper and online media |
|                                     | Local billboards and newspaper articles | Provider referral system | News media interviews |
| Provider engagement                 | Paper-based referral forms sent to provider offices | Provider and urgent care sites via email, fax, and phone | Provider and urgent care sites via email, fax, and phone |

8 AS Lambrou et al. https://doi.org/10.1017/dmp.2022.15 Published online by Cambridge University Press
Table 5. Monoclonal antibody infusion therapy and process recommendations for the COVID-19 pandemic and future emerging public health threats

| Monoclonal antibody recommendation | Description |
|-----------------------------------|-------------|
| **Incorporate monoclonal antibodies into pandemic preparedness and response and existing health systems as an early intervention** | Monoclonal antibodies can: |
| | Be manufactured rapidly after neutralizing antibody identification |
| | Provide immediate immunologic support when other medical counter measures (MCMs) are under development or require time to achieve full effectiveness such as vaccines |
| | Serve as prophylaxis for individuals at high risk for infection |
| | Adapt to many forms of deployment during a public health emergency |
| | Integrate into existing health system processes such as existing outpatient infusion processes and ED/Urgent Care med visits |
| **Strengthen process workflow and environment flexibility during public health emergency** | Adjust monoclonal antibody administration process to policy changes |
| | Critical to monitor and evaluate process workflow to optimize and remain flexible to public health emergency conditions |
| | Adapt monoclonal antibody administration environment to infection control, weather, drug, and staffing changes |
| **Adapt staffing models to minimize burden, and maximize targeted skills** | Establish workflow with minimal staffing needs |
| | Balance staffing needs with other emergency response activities |
| | Integrate non-traditional health care workers such as medical volunteers and paramedics |
| **Infusion site location expansion and innovative administration** | Community-based sites: multiple medical centers partner to implement a monoclonal antibody infusion site, share resources and staffing, and minimize individual burden |
| | Rapid testing adjacent sites: co-locate monoclonal antibody site with rapid testing capabilities to refer and immediately treat patients |
| | Car-based infusion or injection: alleviate the physical environment by delivering monoclonal antibodies and observing patients in cars |
| | Home administration: administer monoclonal antibodies in nursing homes or long-term care facilities |
| **Ensure strong engagement and equity** | Engage with local communities to dispel misinformation and disinformation regarding treatments |
| | Empower communities and providers with the knowledge of new therapeutic options and impact data |
| | Ensure monoclonal antibody allocation equity by directing information to populations that are vulnerable, most in need, and likely to meet eligibility criteria |
| **Improved therapy formulations and delivery mechanisms** | Expand and improve routes of drug administration for therapies, especially rapid methods such as subcutaneous, intramuscular, and microneedle transdermal administration |
| | Strengthen temperature stability and minimize drug product preparation requirements |
| **Standard data collection and effectiveness study integration for outpatients** | Establish data collection standards for early adopters of monoclonal antibody infusion to permit rapid assessment and large-scale evaluation |
| | Pair monoclonal antibody distribution with data collection network to better understand the therapeutic impact during EUA periods |
| **Sustainable use and public health integration through other disease targets** | Promote monoclonal antibodies in emerging infectious disease preparedness and response toolkit |
| | Build upon the therapeutics momentum from the pandemic |
| | Continue innovative monoclonal antibody research and study delivery mechanisms and emergency implementation techniques |
| | Partner with organizations researching the application of monoclonal antibodies for other disease targets and public health threats |

accommodate more patients than their average numbers. Community and provider engagement is critical for any new public health measure, but even more so during a pandemic, as all 3 sites reported challenges addressing misinformation and disinformation on COVID-19 treatments and control in their local communities.

The limitations of this descriptive analysis are rooted in its small sample size of 3 sites and limited geographic scope. However, this study has been uniquely conducted during the pandemic to inform ongoing public health action and infusion site implementation during this emergency. These therapies are not yet widely available internationally, and lessons learned now in the United States may
be generalizable to other settings implementing monoclonal antibodies for an emerging infectious disease.

**Recommendations for Current and Future Use**

The monoclonal antibody infusion site process description and assessment has informed general recommendations for the current implementation and future use of these therapies to tackle public health emergencies (Table 5). For current use, this monoclonal antibody infusion site process assessment has also supported the development of a data-informed decision support tool called “The mAbs Calculator” hosted for free public use on the ASPR Public Health Emergency website.14 This calculator provides infusion metrics, recommendations, and data visualizations for monoclonal antibody infusion sites to plan and adapt their staffing, resources, and outputs based upon capacity and workflow inputs.15 Infusion process workflow and environment adaptability are critical as infusion times, requirements, and staffing change in emergencies. A primary recommendation is to build workflows that can be sustainably maintained in existing pandemic response ecosystems. Optimal staffing models require the minimal number of individuals with the appropriate targeted skills. Medical volunteers, paramedics, and other medical emergency support staff can be leveraged from local services to reduce the burden on the health system.

In public health emergencies, it is important to innovatively expand potential monoclonal antibody administration sites beyond traditional settings. A future outbreak or pandemic could be ignited by a more transmissible pathogen, in which it would be prudent to further minimize staff and patient interactions. One potential solution is patient infusion or injection of a monoclonal antibody therapy with observation in patients’ vehicles, decreasing interactions in a physical environment, space, and indoor infection control systems. This intervention may not be suitable for all settings and vulnerable populations, but it can reduce the strain on physical environments and decrease potential transmission events between patients and health care workers. Further integration of monoclonal antibody delivery into communities could occur by co-locating infusion sites with rapid testing sites so that patients notified of positivity and meeting eligibility criteria could easily access treatment. Infusions and injections may also be administered in the home,16 removing the need for a physical environment, but potentially increasing the staffing needs and time. As novel treatments arise, such as monoclonal antibodies, strong engagement with the public and equitable distribution of such therapeutics to vulnerable populations is critical.17 Currently, monoclonal antibodies are delivered via intravenous infusion and subcutaneous administration and research may soon enable intramuscular delivery.18 Expanding and improving drug administration routes, especially more rapid methods such as subcutaneous, intramuscular, and microneedle transdermal administration, can support more rapid and less intensive therapy deployment. There is evidence that current monoclonal antibody therapies may show reduced neutralization and potential effectiveness against novel SARS-CoV-2 virus variants to which the drugs were not optimized.20 However, a strength of monoclonal antibodies is rooted in their adaptability and rapid production. Monoclonal antibody therapies can act as a platform biologic that can be updated as emerging infectious diseases evolve and evade targeting.

Measuring the effectiveness of new therapies, especially in outpatient populations, during a public health emergency, is difficult because resources are focused on saving lives. Establishing site data collection standards to rapidly assess effectiveness and pairing these with the early distribution of new therapies during an emergency, such as monoclonal antibodies, would improve large-scale evaluation. Implementation lessons learned can be translated for the next pandemic. Innovative research, delivery mechanisms, and implementation techniques for monoclonal antibodies must be further studied and optimized, and this can be accomplished through the lens of other pathogens and public health threats.

The emerging infectious disease preparedness and response toolkit is growing to incorporate monoclonal antibodies, and building upon the therapeutics momentum in the current pandemic is important for the next pandemic.

**Supplementary material.** To view supplementary material for this article, please visit https://doi.org/10.1017/dmp.2022.15

**Acknowledgments.** The authors acknowledge the significant efforts of the members of the Disaster Medical Assistance Teams (DMATs) who coordinated the monoclonal antibody infusion site setup, initiation, and integration with the collaborating medical centers. The authors would also like to thank the incredible infusion site leadership, implementation, and clinical staff at El Centro Regional Medical Center (El Centro, CA), TMC HealthCare (Tucson, AZ), and Sunrise Hospital and Medical Center (Las Vegas, NV), who provided extensive time and support for this study.

**Funding statement.** This study was supported by the US Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR) through HHS/ASPR contract #: 75A50121C00003.

**Conflict(s) of interest.** None of the authors received any payments or influence from a third-party source for the work presented, and none reports any potential conflict of interest.

**References**

1. Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. *JAMA*. 2020;324(13):131-132. doi: 10.1001/jama.2020.10245
2. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 2020;584:115-119. doi: 10.1038/s41586-020-2380-z
3. COVID-19 Treatment Guidelines, Anti-SARS-CoV-2 Monoclonal Antibodies. National Institutes of Health (NIH). Published 2021. Accessed April 1, 2021. [https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/](https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/)
4. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. *N Engl J Med*. 2020;384:229-237. doi: 10.1056/NEJMoar202984
5. Weirich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. *N Engl J Med*. 2020;384:238-251. doi: 10.1056/NEJMoar2035002
6. Gottlieb RL, Nirulla A, Chen P, et al. Effect of bamlanivimab as mono-therapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. *JAMA*. 2021;325:632-644. doi: 10.1001/jama.2021.0202
7. Rainwater-Lovett K, Redd JT, Stewart MA, et al. Real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse population in the United States. *Open Forum Infect Dis*. 2021;8:ofab398. doi: 10.1093/ofid/ofab398
8. Bariola JR, McCreary EK, Wadas RJ, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with severe acute respiratory syndrome coronavirus 2 infection. *Open Forum Infect Dis*. 2021;8(7):ofab254. doi: 10.1093/ofid/ofab254
9. Webb BJ, Buckel W, Vento T, et al. Real-world effectiveness and tolerability of monoclonal antibody therapy for ambulatory patients with early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331. Published 2021 Jun 23. doi: 10.1093/ofid/ofab331

10. Rizk, J. G, Forthal DN, Kalantar-Zadeh K, et al. Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic. Drug Discov Today. 2020. doi: 10.1016/j.drudis.2020.11.025

11. Donnenberg VS. AAMC discusses monoclonal antibody therapeutics for SARS-CoV-2 infection. J Clin Pharmacol. 2021;61:280-281. doi: 10.1002/jcph.1820

12. Cohen MS. Monoclonal antibodies to disrupt progression of early COVID-19 infection. N Engl J Med. 2021;384:289-291. doi: 10.1056/NEJMe2034495

13. Sempowski GD, Saunders KO, Acharya P, et al. Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19. Cell. 2020;181:1458-1463. doi: 10.1016/j.cell.2020.05.041

14. The mAbs Calculator. US Department of Health & Human Services (HHS). Published June 22, 2021. Accessed November 17, 2021. https://www.phe.gov/emergency/mAbs-calculator/Pages/default.aspx

15. Çağlayan C, Thornhill J, Stewart MA, et al. Staffing and capacity planning for SARS-CoV-2 monoclonal antibody infusion facilities: a performance estimation calculator based on discrete-event simulations. Front Public Health. 2022(2415). doi: 10.3389/fpubh.2021.770039

16. Malani AN, LaVasseur B, Fair J et al. Administration of monoclonal antibody for COVID-19 in patient homes. JAMA Netw Open. 2021;4:e2129388–e2129388. doi: 10.1001/jamanetworkopen.2021.29388

17. Bollyky TJ, Gostin LO, Hamburg MA. The equitable distribution of COVID-19 therapeutics and vaccines. JAMA. 2020;323:2462-2463. doi: 10.1001/jama.2020.6641

18. Lanini S, Milleri S, Andreano E, et al. A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccination. medRxiv. 2021. doi: 10.1101/2021.08.03.21261441

19. Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. J Pharm Investig. 2021;51:503-517. doi: 10.1007/s40005-021-00512-4

20. Hu J, Peng P, Wang K, et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cell Mol Immunol. 2021;18:1061-1063. doi: 10.1038/s41423-021-00648-1